Published in Arterioscler Thromb Vasc Biol on April 28, 2005
Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? Respir Res (2006) 1.51
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 1.15
Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol (2007) 1.10
Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem (2008) 1.09
Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol (2011) 0.94
C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res (2009) 0.93
Coupling of Fcγ receptor I to Fcγ receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function. Circ Res (2011) 0.90
Linking inflammation and thrombosis: Role of C-reactive protein. World J Cardiol (2010) 0.89
The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection. Endocr Metab Immune Disord Drug Targets (2008) 0.89
C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta. Am J Physiol Heart Circ Physiol (2008) 0.88
Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One (2013) 0.88
Classical pathway complement activation on human endothelial cells. Mol Immunol (2006) 0.87
Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy? Clin Exp Immunol (2010) 0.84
Early expression of FcgammaRI (CD64) on monocytes of cardiac surgical patients and higher density of monocyte anti-inflammatory scavenger CD163 receptor in "on-pump" patients. Mediators Inflamm (2008) 0.83
The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating β-endorphin release from spinal microglia. Br J Pharmacol (2014) 0.83
Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction. PLoS One (2013) 0.80
The pro-atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine. J Inflamm (Lond) (2012) 0.80
High sensitivity C-reactive protein levels in Acute Ischemic Stroke and subtypes: A study from a tertiary care center. Iran J Neurol (2013) 0.79
Medically relevant assays with a simple smartphone and tablet based fluorescence detection system. Sensors (Basel) (2015) 0.79
Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations. BMC Med Genet (2009) 0.79
Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cells. Mol Immunol (2013) 0.77
Fcγ receptors and ligands and cardiovascular disease. Circ Res (2015) 0.77
Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease. J Cardiovasc Transl Res (2016) 0.77
Altered in vitro endothelial repair and monocyte migration in obstructive sleep apnea: implication of VEGF and CRP. Sleep (2014) 0.76
Fcγ Receptors in Solid Organ Transplantation. Curr Transplant Rep (2016) 0.75
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes (2006) 2.65
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol (2005) 2.40
Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care (2010) 2.39
Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol (2008) 2.29
High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes (2008) 2.23
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine (2011) 1.91
Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature (2008) 1.88
Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev (2008) 1.86
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum (2005) 1.72
Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol (2012) 1.67
Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem (2005) 1.53
Oxidative stress and atherosclerosis. Pathophysiology (2006) 1.52
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol (2008) 1.51
Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr (2005) 1.51
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes (2005) 1.50
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab (2010) 1.45
Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler Thromb Vasc Biol (2004) 1.43
Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun (2002) 1.42
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.42
Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol (2009) 1.40
Quantification of daratumumab in the serum protein electrophoresis. Clin Chem Lab Med (2016) 1.39
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol (2010) 1.37
Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol (2011) 1.34
Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J Immunol (2002) 1.34
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol (2006) 1.32
Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med (2007) 1.30
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab (2011) 1.25
Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes (2002) 1.24
C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol (2002) 1.23
Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr (2002) 1.23
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol (2006) 1.21
Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab (2003) 1.19
C-reactive protein at the interface between innate immunity and inflammation. Expert Rev Clin Immunol (2008) 1.18
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17
Innate immunity genes influence the severity of acute appendicitis. Ann Surg (2004) 1.16
C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 1.15
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr (2007) 1.14
Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens (2005) 1.14
Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol (2005) 1.13
CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol (2008) 1.10
Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol (2005) 1.10
Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol (2013) 1.10
Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum (2006) 1.08
C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcgamma receptors. J Immunol (2007) 1.08
Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab (2010) 1.06
CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol (2006) 1.04
Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci U S A (2011) 1.04
Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism (2010) 1.02
Failure of vitamin E in clinical trials: is gamma-tocopherol the answer? Nutr Rev (2005) 1.01
Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab (2005) 1.01
Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol (2011) 1.01
C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol (2005) 1.00
High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism (2008) 1.00
Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr (2002) 0.99
Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr (2006) 0.98
Coenzyme Q10 supplementation and heart failure. Nutr Rev (2007) 0.98
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol (2007) 0.98
Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem (2010) 0.97
Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol (2004) 0.97
Anti-inflammatory effects of alpha-tocopherol. Ann N Y Acad Sci (2004) 0.97
Statins and biomarkers of inflammation. Curr Atheroscler Rep (2007) 0.96
TLR2 expression and signaling-dependent inflammation impair wound healing in diabetic mice. Lab Invest (2010) 0.96
Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism (2004) 0.96
Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol (2012) 0.95
Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem (2011) 0.95
Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis (2006) 0.94
C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem (2008) 0.94
Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis (2008) 0.93
Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med (2004) 0.93
C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem (2011) 0.93
Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology (2009) 0.93
Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol (2009) 0.92
Pentraxins and Fc receptors. Immunol Rev (2012) 0.92
Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic Biol Med (2005) 0.92
Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem (2008) 0.92
The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev (2005) 0.92
C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res (2009) 0.92
Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol (2003) 0.91
Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord (2010) 0.91
C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol (2006) 0.90
Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids (2002) 0.90
Transforming growth factor-β, macrophage colony-stimulating factor and C-reactive protein levels correlate with CD14(high)CD16+ monocyte induction and activation in trauma patients. PLoS One (2012) 0.90
Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab Syndr Relat Disord (2012) 0.90
C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to Fc gamma R on dendritic cells. J Immunol (2007) 0.89
C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptors. J Immunol (2006) 0.89